Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

Fig. 5

Effect of minocycline WP on histological change after afatinib administration, HE staining. a afatinib administration only, b treatment with minocycline WP from the 10th day after administration of afatinib, c treatment with minocycline WP from the 5th day after administration of afatinib, and d pretreatment with minocycline WP before administration of afatinib for 3 days

Back to article page